- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study: Limiting NPs' scope of practice leads to higher costs
- CVS Caremark to stop selling tobacco in all store locations
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.
Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.
“Lupron Depot is an important treatment option for many patients with advanced prostate cancer,” Abbott VP global pharmaceutical development Eugene Sun said. “Approval of a new six-month formulation means that physicians and patients who have chosen Lupron Depot now have an additional treatment option.”